Human Epidermal Growth Factor Receptor 2 (Her-2) and S-1 Adjuvant Chemotherapy in Stage 2/3 Gastric Cancer Patients Who Underwent D2 Gastrectomy

Overview

Journal Surg Today

Specialty General Surgery

Date 2013 Mar 21

PMID 23512532

Citations 2

Authors

Toru Aoyama

Takaki Yoshikawa

Yohei Miyagi

Yoichi Kameda

Junya Shirai

Tsutomu Hayashi

Haruhiko Cho

Takashi Oshima

Norio Yukawa

Yasushi Rino

Munetaka Masuda

Akira Tsuburaya

Affiliations

Soon will be listed here.

Abstract

Purposes: The trastuzumab for Gastric Cancer study newly defined tumors that were positive for human epidermal receptor-2 (Her-2) and created a Her-2-oriented treatment strategy that is also applicable in the adjuvant setting for stage 2/3 cancers. However, there is currently no information available on the rate of Her-2 positivity and the relapse-free survival (RFS) stratified by Her-2 status in stage 2/3 patients.

Methods: The Her-2 status, defined by the current standard method, was examined in 100 gastric cancer patients who underwent curative D2 surgery, who were pathologically diagnosed with stage 2/3 cancer, and received adjuvant S-1 chemotherapy between June 2002 and December 2011.

Results: Ten of the 100 patients were Her-2 positive. Her-2-positive status was more frequently seen in tumors with a differentiated histology. The 5-year RFS rate was 56.3 % in Her-2-positive cases, and 48.8 % in Her-2 negative cases, which was not significantly different (P = 0.786).

Conclusions: The Her-2-positive rate for stage 2/3 gastric cancer patients was low, at only 10 %. Although the RFS was not significantly different based on the Her-2 status, the low positive rate made interpretation difficult. A multi-center study with a large sample size is necessary to clarify the prognostic impact of Her-2 in stage 2/3 gastric cancer patients.

Citing Articles

The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.

Lei Y, Huang J, Zhao Q, Jiang N, Xu H, Wang Z World J Surg Oncol. 2017; 15(1):68.

PMID: 28327158 PMC: 5359900. DOI: 10.1186/s12957-017-1132-5.

Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis.

Gu J, Zheng L, Wang Y, Zhu M, Wang Q, Li X Tumour Biol. 2014; 35(6):5315-21.

PMID: 24557541 DOI: 10.1007/s13277-014-1693-7.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View

Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H . Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1. Gastric Cancer. 2011; 14(3):274-8. DOI: 10.1007/s10120-011-0038-0. View

Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A . Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2009; 126(3):651-5. DOI: 10.1002/ijc.24746. View

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-20. DOI: 10.1056/NEJMoa072252. View

Tanner M, Hollmen M, Junttila T, Kapanen A, Tommola S, Soini Y . Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005; 16(2):273-8. DOI: 10.1093/annonc/mdi064. View

Hudis C . Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007; 357(1):39-51. DOI: 10.1056/NEJMra043186. View

Bang Y, Kim Y, Yang H, Chung H, Park Y, Lee K . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315-21. DOI: 10.1016/S0140-6736(11)61873-4. View

Ohtsu A, Yoshida S, Saijo N . Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006; 24(14):2188-96. DOI: 10.1200/JCO.2006.05.9758. View

10.

Smith I, Procter M, Gelber R, Guillaume S, Feyereislova A, Dowsett M . 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369(9555):29-36. DOI: 10.1016/S0140-6736(07)60028-2. View

11.

Shitara K, Yatabe Y, Matsuo K, Sugano M, Kondo C, Takahari D . Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer. 2012; 16(2):261-7. DOI: 10.1007/s10120-012-0179-9. View

12.

Okines A, Verheij M, Allum W, Cunningham D, Cervantes A . Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v50-4. DOI: 10.1093/annonc/mdq164. View

13.

Tsujitani S, Saito H, Wakatsuki T, Ikeguchi M, Shirabe K, Morita M . Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today. 2011; 42(3):225-32. DOI: 10.1007/s00595-011-0062-z. View

14.

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72. DOI: 10.1056/NEJMoa052306. View

15.

Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S . Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991; 51(3):1034-8. View

16.

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

17.

Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T . Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy. Ann Surg Oncol. 2011; 19(5):1568-74. DOI: 10.1245/s10434-011-2158-5. View

18.

Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y . A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial. Jpn J Clin Oncol. 2005; 35(11):672-5. DOI: 10.1093/jjco/hyi179. View